UK doctors to seek permission to create baby with DNA from three people
By Ian Sample,
The Guardian
| 11. 30. 2016
Specialists poised to offer mitochondrial replacement therapy if government’s fertility regulator approves the treatment
Doctors will seek permission this month to create Britain’s first baby from the DNA of three people if the government’s fertility regulator approves the treatment for carefully chosen patients.
Specialists in Newcastle are ready to offer mitochondrial replacement therapy (MRT) to women who are in danger of passing on devastating and often fatal genetic disorders to their children. The conditions affect about one in 10,000 births.
A scientific review commissioned by the Human Fertilisation and Embryology Authority (HFEA) concluded on Wednesday that the therapy should be approved for “cautious clinical use” when children are at risk of inheriting specific genetic diseases.
The HFEA will now consider the findings and invite clinics to apply for licences if it endorses the recommendations at a meeting on 15 December. Last year, parliament changed the law to allow MRT, but scientists continued with further experiments to assess the treatment’s safety.
The Newcastle team has already selected patients who may be suitable for the therapy and plans to submit a licence...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
